Zepbound Cost (2026): With Insurance, Without, and the Savings Card

Zepbound is Eli Lilly's tirzepatide product approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. It is the same molecule as Mounjaro, but Mounjaro carries a type 2 diabetes indication and is a different product with different pricing — do not treat quotes for one as quotes for the other. What makes Zepbound's price confusing is that Lilly has cut and restructured it repeatedly, so most of the numbers circulating online are stale. Everything below was read off Lilly's own pages on August 21, 2026.

Zepbound Price: List Price vs What People Actually Pay

"List price" — the wholesale acquisition cost, or WAC — is the price at which Lilly sells to wholesalers. It is not a price a patient is quoted, and for Zepbound it has become close to irrelevant for anyone paying cash, because Lilly now runs its own lower-priced self-pay channel. Lilly publishes current list prices on its pricing information site, and the savings-card terms reference WAC directly: for a commercially insured patient whose plan does not cover the single-dose pen, the terms cap card savings at "wholesale acquisition cost minus $499."

The practical read: the list price is the number the self-pay programs exist to route around. A cash patient going through LillyDirect is quoted $299 to $449 a month depending on dose; a patient whose commercial plan covers the pen is quoted as little as $25 a fill. The list price sits above both. Get the current WAC from Lilly's pricing information site rather than a third-party blog — the figure moved during 2026, and stale numbers are the most common error in Zepbound cost articles.

LillyDirect Zepbound Cost: The Self-Pay Price Per Dose

LillyDirect is Lilly's own direct-to-patient pharmacy, and it is where the published self-pay prices live. Zepbound comes in three formats there, and they are priced on two completely different logics — this is the part most people get wrong.

The three formats differ in more than price:

• Single-dose vial. Lilly describes it as exclusively available through LillyDirect and self-pay only. A "month" is defined as 28 days and 4 single-dose vials. Needles and syringes must be purchased separately.
• Single-patient-use KwikPen. Self-pay accepted and select insurance accepted. A "month" is 28 days and 1 KwikPen. A pen needle purchase is required.
• Single-dose pen. This is the insurance route, not the cash route. Lilly prices it through the savings card at as little as $25 for up to a 3-month prescription for eligible, commercially insured patients with coverage. A needle is included in each pen.

One more piece of arithmetic worth doing before you budget: Lilly defines a "month" as 28 days, not a calendar month. Thirteen 28-day cycles fit in a year. So a $449 "monthly" price is closer to $5,800 a year than $5,400, and the same is true at every tier. Budget on the cycle, not the calendar.

The Zepbound Savings Card: What the Terms Actually Say

This is the most-searched and most-misreported part of Zepbound pricing. The Zepbound Savings Card is a manufacturer copay-assistance program with written terms, and those terms are more specific than the marketing headline. Three things are true of every tier: the program is not insurance, savings are subject to monthly and annual limits, and Lilly reserves the right to terminate, rescind, revoke or amend the program at any time, without notice, for any reason. As published, the card expires and savings end on 12/31/2026.

Who the eligibility terms exclude

The exclusion that catches the most people is government insurance. The terms require that you are not enrolled in any state, federal, or government-funded healthcare program, and Lilly names them: Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE/CHAMPUS, and state prescription drug assistance programs. This is not a Zepbound quirk — federal anti-kickback rules keep manufacturer copay cards away from government beneficiaries across the industry.

Other conditions in the published terms: you need a prescription for an FDA-approved use consistent with the labeling; participation requires a valid patient HIPAA authorization; and if your plan participates in an alternate funding program that requires you to apply to the savings card as a condition of coverage, the terms state you are prohibited from using the program.

Is There a Zepbound Manufacturer Coupon?

Not in the sense most searches mean. There is no public Zepbound coupon code you enter at checkout, and no printable discount that works for everyone. What Lilly operates are two named programs with eligibility rules and enrollment:

1. The Zepbound Savings Card — copay assistance for commercially insured patients, split into the covered and not-covered tiers above.
2. The Zepbound KwikPen Self-Pay Savings Card — a cash-patient program covered in the next section.

Third-party discount cards are a separate thing entirely. They are not manufacturer programs, they do not stack with manufacturer assistance, and the price they show is a negotiated cash price at a specific pharmacy on a specific day. If you are comparing, compare the all-in number for the same dose in the same week: the LillyDirect self-pay price, the post-savings-card price your pharmacy actually quotes, and any discount-card price. Then pick.

Zepbound KwikPen Coupon and the Self-Pay Card

The KwikPen has its own program, and this is where the naming gets genuinely confusing, because two different cards carry the same price ladder for two different people:

• The Savings Card KwikPen tier applies if you have commercial drug insurance that does not cover the KwikPen. Published prices: $299 for 2.5 mg (maximum monthly savings up to $215), $399 for 5 mg (up to $115), $449 for 7.5 mg (up to $65), and $449 for 10 mg, 12.5 mg or 15 mg (up to $271).
• The KwikPen Self-Pay Savings Card applies to self-paying cash patients and carries the identical ladder. Its terms require that you not seek or accept reimbursement for the cost from any third-party payer — private insurance or government program — and that you not apply the cost toward a deductible or true out-of-pocket total.

Both cap the KwikPen at a maximum of 11 prescription fills per calendar year. Put that next to the 28-day cycle: a year of continuous 28-day fills is about 13 fills, and the card as written covers 11 of them. Plan for the last fills of a calendar year to price differently, and ask the pharmacy to confirm before you assume December looks like June.

The self-pay card terms also describe a post-transaction reimbursementpath: if you refilled inside the 45-day window and were otherwise eligible but Lilly could not verify it at the point of sale, you can submit a claim for the difference through the program's patient portal. As published, those claims must be submitted or postmarked no later than March 31, 2027. Keep your pharmacy receipts.

Zepbound Cost With Insurance

There is no single answer here, and any page that gives you one is guessing. Coverage for weight-management medication varies more than almost any other drug category. Lilly's own savings page reflects this: before it shows you anything, it asks you to select your insurance type from commercial-covered, commercial-not-covered, Medicare, other government, no insurance, or not sure. Those are genuinely different price worlds.

Three things drive what you pay:

• Formulary status. Whether Zepbound is covered at all, and on which tier. Specialty tiers carry higher cost-share, and that is what the savings card is applied against.
• Prior authorization. Common for weight-management drugs. Expect documentation requirements, and expect the process to take time — which interacts badly with the 45-day refill condition if you are toggling between routes.
• Employer carve-outs. Some employers exclude weight-management drugs from the pharmacy benefit entirely, even on an otherwise generous plan. If that is your situation, you are functionally a self-pay patient and the LillyDirect ladder is your real price.

The useful call to make: phone the number on your insurance card and ask three questions. Is Zepbound on formulary? What tier? Is prior authorization required? Those three answers tell you which column of this page applies to you.

Cheaper Routes Worth Comparing

Zepbound is one product. Tirzepatide is the molecule, and there are other ways to buy access to it — with real trade-offs, not just lower numbers.

• Clinic and telehealth programs. Clinics bundle medication, visits and monitoring into one monthly price. Our tirzepatide cost guide tracks verified per-clinic pricing, each number quoted from the clinic's own site and dated. That page is canonical for program pricing; this one is canonical for what Lilly charges directly.
• The cross-molecule comparison. The cheapest FDA-approved GLP-1 may not be a tirzepatide product at all. See cheapest GLP-1 without insurance and semaglutide vs tirzepatide. The choice is clinical, not only financial.
• Compounded versions — read this honestly. Compounded tirzepatide is not in the same position as compounded semaglutide: the FDA declared the tirzepatide shortage resolved on December 19, 2024, ending the shortage-based pathway that allowed widespread compounding of tirzepatide copies. Our compounded semaglutide guide explains why "compounded" is not a generic. There is no generic tirzepatide in the US.
• Know what you are comparing. Our GLP-1 medications list maps every FDA-approved option to its indication — the fastest way to avoid pricing a diabetes-labeled product as a weight-management one. Browse clinics by state or compare cash-pay services on the price index.

A note on Zepbound vs Mounjaro

Both are tirzepatide and both are made by Lilly, but they are different products with different FDA-approved uses and separate pricing programs. Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity; Mounjaro is approved for type 2 diabetes. A Mounjaro price is not a Zepbound price, and the savings programs are not interchangeable. See Mounjaro vs Ozempic if you are comparing diabetes-labeled products.